Innocuité et efficacité de la rythme de la zone de branche du faisceau gauche par rapport à la thérapie de resynchronisation cardiaque conventionnelle dans l'insuffisance cardiaque (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Jacqueline Beaulieu
- Numéro de téléphone: 1-800-227-3422
- E-mail: jacqueline.beaulieu@bsci.com
Lieux d'étude
-
-
Alabama
-
Huntsville, Alabama, États-Unis, 35801
- Recrutement
- Heart Center Research, LLC
-
Contact:
- John Jennings, Dr.
-
Chercheur principal:
- John Jennings, Dr.
-
Mobile, Alabama, États-Unis, 36608
- Recrutement
- Mobile Infirmary Medical Center
-
Contact:
- Ernest Matthew Quin, Dr.
-
Chercheur principal:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Recrutement
- Mayo Clinic Phoenix
-
Contact:
- Mayank Sardana, MD
-
Chercheur principal:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro, Arkansas, États-Unis, 72401
- Recrutement
- Arrhythmia Research Group
-
Contact:
- Devi Nair, Dr.
-
Chercheur principal:
- Devi Nair, Dr.
-
-
California
-
La Jolla, California, États-Unis, 92037
- Recrutement
- Scripps Memorial Hospital
-
Contact:
- Nicolas Olson, MD
-
Chercheur principal:
- Nicolas Olson, MD
-
Los Angeles, California, États-Unis, 90048
- Recrutement
- Cedars Sinai Medical Center
-
Chercheur principal:
- Ashkan Ehdaie, MD
-
Contact:
- Ashkan Ehdaie, MD
-
Oakland, California, États-Unis, 94609
- Recrutement
- Alta Bates Summit Medical Center
-
Contact:
- Rajan Shah, Dr.
-
Chercheur principal:
- Rajan Shah, Dr.
-
Santa Monica, California, États-Unis, 90404
- Recrutement
- Pacific Heart Institute
-
Contact:
- Stephen Tang, MD
-
Chercheur principal:
- Stephan Tang, MD
-
Torrance, California, États-Unis, 90505
- Recrutement
- Torrance Medical Center
-
Chercheur principal:
- Gene Kim, MD
-
Contact:
- Gene Kim, MD
-
Ventura, California, États-Unis, 93003
- Recrutement
- Cardiology Associates Medical Group, Inc.
-
Contact:
- Jonathan Dukes, Dr.
-
Chercheur principal:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Recrutement
- Washington Hospital Center
-
Contact:
- Cyrus Hadadi, MD
-
Chercheur principal:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota, Florida, États-Unis, 34239
- Recrutement
- Sarasota Memorial Hospital
-
Contact:
- Antonio Moretta, Dr.
-
Chercheur principal:
- Antonio Moretta, Dr.
-
Tampa, Florida, États-Unis, 33613
- Recrutement
- AdventHealth Tampa
-
Chercheur principal:
- Kenneth Yamamura, MD
-
Contact:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30309
- Recrutement
- Piedmont Hospital
-
Contact:
- Kavita Krishnasamy, MD
-
Chercheur principal:
- Kavita Krishnasamy, MD
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory University Hospital
-
Contact:
- Anand Shah, MD
-
Chercheur principal:
- Anand Shah, MD
-
-
Idaho
-
Meridian, Idaho, États-Unis, 83642
- Recrutement
- St. Luke's Idaho Cardiology Associates
-
Contact:
- Justice Oranefo, MD
-
Chercheur principal:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale, Illinois, États-Unis, 60521
- Recrutement
- University of Chicago
-
Contact:
- Shrinath Yeshwant, MD
-
Chercheur principal:
- Shrinath Yeshwant, MD
-
Naperville, Illinois, États-Unis, 60540
- Retiré
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46250
- Recrutement
- Community Heart and Vascular Hospital
-
Contact:
- Krishna Malineni, MD
-
Chercheur principal:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- Recrutement
- University of Iowa Hospitals and Clinics
-
Chercheur principal:
- Paari Dominic, MD
-
Contact:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40207
- Recrutement
- Baptist Hospital East Louisville
-
Chercheur principal:
- Kevin Parrott, MD
-
Contact:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River, Massachusetts, États-Unis, 02720
- Recrutement
- Southcoast Physicians Group
-
Contact:
- Arnoldas Giedrimas, MD
-
Chercheur principal:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- University of Michigan Hospitals
-
Chercheur principal:
- Thomas Crawford, MD
-
Contact:
- Thomas Crawford, MD
-
Grand Rapids, Michigan, États-Unis, 49525
- Recrutement
- Corewell Health
-
Contact:
- Jawad Wassim, MD
-
Chercheur principal:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth, Minnesota, États-Unis, 55805
- Retiré
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud, Minnesota, États-Unis, 56303
- Retiré
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown, New Jersey, États-Unis, 07932
- Recrutement
- Morristown Medical Center
-
Contact:
- Michael Katz, MD
-
Chercheur principal:
- Michael Katz, MD
-
-
New York
-
Albany, New York, États-Unis, 12211
- Recrutement
- Capital Cardiology Associates
-
Contact:
- Rizwan Alimohammad, MD
-
Chercheur principal:
- Rizwan Alimohammad, MD
-
Flushing, New York, États-Unis, 11355
- Recrutement
- New York Hospital Queens
-
Contact:
- Seth Goldbarg, Dr.
-
Chercheur principal:
- Seth Goldbarg, Dr.
-
New York, New York, États-Unis, 10021
- Recrutement
- Weill Cornell Medical University
-
Contact:
- Jim Cheung, Dr.
-
Chercheur principal:
- Jim Cheung, Dr.
-
New York, New York, États-Unis, 14621
- Recrutement
- Rochester General Hospital
-
Contact:
- Dmitry Chuprun, MD
-
Chercheur principal:
- Dmitry Chuprun, MD
-
Syracuse, New York, États-Unis, 13057
- Recrutement
- SUNY-Upstate Medical University
-
Contact:
- Jorge Romero, MD
-
Chercheur principal:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Recrutement
- Sanger Heart and Vascular Institute
-
Contact:
- Navid Nafissi, MD
-
Chercheur principal:
- Navid Nafissi, MD
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke University Medical Center
-
Contact:
- Daniel Friedman, MD
-
Chercheur principal:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43219
- Recrutement
- Mount Carmel Health System
-
Contact:
- Kamel Addo, MD
-
Chercheur principal:
- Kamel Addo, MD
-
Columbus, Ohio, États-Unis, 43214
- Recrutement
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
Contact:
- Anish Amin, MD
-
Chercheur principal:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- Penn Presbyterian Medical Center
-
Contact:
- John Bullinga, MD
-
Chercheur principal:
- John Bullinga, MD
-
Wilkes-Barre, Pennsylvania, États-Unis, 18702
- Recrutement
- Geisinger Wyoming Valley
-
Chercheur principal:
- Pugazhendhi Vijayaraman, MD
-
Contact:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57108
- Recrutement
- Avera Heart Hospital of South Dakota
-
Contact:
- Christopher Stanton, Dr.
-
Chercheur principal:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37205
- Recrutement
- St.Thomas Health
-
Contact:
- Ricardo Lugo, MD
-
Chercheur principal:
- Ricardo Lugo, MD
-
-
Texas
-
Plano, Texas, États-Unis, 75093
- Recrutement
- Heart Hospital Baylor Plano
-
Contact:
- Mustafa Dohadwala, MD
-
Chercheur principal:
- Mustafa Dohadwala, MD
-
Tyler, Texas, États-Unis, 75701
- Recrutement
- Christus Trinity Mother Frances Health System
-
Contact:
- Stanislov Weiner, Dr.
-
Chercheur principal:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- Recrutement
- University of Virginia Medical Center
-
Chercheur principal:
- Pamela Mason, MD
-
Contact:
- Pamela Mason, MD
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur actif: CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
Expérimental: LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Délai: Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
Délai: 12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Win ratio composite assessment
Délai: Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Délai: Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
Délai: 12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- C2403
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .